Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

Other results

In 2008, net financial income amounted to EUR5.5 million compared to EUR5.2 million in 2007 and represents mainly the returns on the financial investments of the Group's cash, cash equivalents and financial instruments.

The income tax expense incurred by NicOx in 2008 relates to its subsidiaries and amounted to EUR0.1 million, identical to 2007.

Net result

The net loss reached EUR73.9 million in 2008 compared to EUR32.1 million in 2007. As indicated above, this very significant increase in net loss in 2008 is due to the strong increase of research and development expenses associated with naproxcinod and from the considerable decrease in the revenues recognized in 2008.

Balance sheet items

The indebtedness incurred by NicOx is mainly short-term operating debt. On December 31, 2008, the Company's current liabilities amounted to EUR21.2 million, including EUR16.2 million in accounts payable to suppliers and external collaborators, EUR2.1 million in accrued compensation for employees, EUR1.5 million in taxes payable, EUR1.1 million in deferred revenues due to payments received under collaboration agreements and EUR0.3 million for other liabilities.

In 2008, NicOx granted to Archimica a loan of EUR6.0 million as part of the financial terms of the manufacturing and supply agreement with this company. Following the termination of the agreement in November 2008, EUR5.0 million out of the EUR6.0 million loan were forgiven in accordance with the terms of the agreement and Archimica remains liable to NicOx, as of December 31, 2008, of an amount of EUR0.9 million with regards to this loan. Considering there is a risk for the recovery of this sum, the Company has decided to depreciate partially this asset and has booked as of December 31, 2008 a contingency provision for an amount of EUR0.5 million.

On December 31, 2008, the Co
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... July 25, 2014 Research and ... "Global Metabolomics Market 2014-2018" report to their ... Metabolomics or Metabonomics is the scientific ... become a new experimental technique that is being ... sciences. Metabolites are small molecules that are present ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... May 11 Amicus Therapeutics (Nasdaq: ... Matthew R. Patterson, will be presenting at the upcoming Bank ... Mr. Patterson,s presentation is scheduled to begin on Wednesday, ... live webcast of the presentation by logging on to the ...
... NEW YORK, May 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... to,improving health through the development, manufacture and commercialization of,a ... products in China,today announced financial results for the first ... Financial Results , Revenue ...
... May 9 Oxford Biomedica,s,second attempt to dismiss Bavarian ... Instead of denying infringement, Oxford Biomedica,made yet another attempt ... TroVax(R) was still evaluated in clinical trials. The court ... based on the,substance of the patents. , ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2009 Financial Results 2American Oriental Bioengineering Reports First Quarter 2009 Financial Results 3American Oriental Bioengineering Reports First Quarter 2009 Financial Results 4American Oriental Bioengineering Reports First Quarter 2009 Financial Results 5American Oriental Bioengineering Reports First Quarter 2009 Financial Results 6American Oriental Bioengineering Reports First Quarter 2009 Financial Results 7The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... from over 18,000 patients, scientists have identified more ... Parkinson,s disease, including six that had not been ... Genetics , was partially funded by the National ... working in NIH laboratories. , "Unraveling the genetic ... multiple mechanisms involved in this complex disease, and ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... Just as scientists finished sequencing the human genome, they ... DNA produces proteins to sustain life, they found microRNA. ... channel in biology, allowing scientists to more closely examine ... tick. "This is a pivotal mechanism for solving ...
... Ore Oregon Health & Science University researchers, along ... uncovering new information about the mind by studying the ... this research will one day provide new tools for ... treatments. The researchers, latest findings are published in the ...
... Universit de Montreal (UdeM) and the Montreal Neurological Institute ... support nerve cell (neuron) survival also play an active ... the eye. The findings, published this week in The ... streamlined therapies for a variety of acute and chronic ...
Cached Biology News:Meet DNA's personal assistants 2OHSU researchers study the idling brain 2Cell's split personality is a major discovery into neurological diseases 2
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
Applications: ISH...
... ZMD.420. Immunogen: Recombinant human ... Specific for the ~44 kDa ... Human (positive control: IFN-Gamma-stimmulated Human ... sequence homology reactivity with mouse ...
Biology Products: